Usefulness and performance evaluation of serum KL-6 and SP-A assays in healthy individuals and patients with interstitial lung disease.

[1]  Xia Li,et al.  Complex Evaluation of Surfactant Protein A and D as Biomarkers for the Severity of COPD , 2022, International journal of chronic obstructive pulmonary disease.

[2]  Wenxiang Chen,et al.  Comparability of thyroid-stimulating hormone immunoassays using fresh frozen human sera and external quality assessment data , 2021, PloS one.

[3]  Denise L. Smith,et al.  Cardiovascular Disease Risk Factors by BMI and Age in United States Firefighters , 2021, Obesity.

[4]  E. Cavigli,et al.  Ground-glass opacity (GGO): a review of the differential diagnosis in the era of COVID-19 , 2021, Japanese Journal of Radiology.

[5]  C. Ryerson,et al.  Update in Interstitial Lung Disease 2020. , 2021, American journal of respiratory and critical care medicine.

[6]  A. Rachow,et al.  Post-Tuberculosis Lung Disease: Clinical Review of an Under-Recognised Global Challenge , 2021, Respiration.

[7]  G. Gudmundsson,et al.  Interstitial lung abnormalities – current knowledge and future directions , 2021, European clinical respiratory journal.

[8]  M. Panteghini,et al.  Verification of Harmonization of Serum Total and Free Prostate-Specific Antigen (PSA) Measurements and Implications for Medical Decisions. , 2020, Clinical chemistry.

[9]  V. Gudnason,et al.  The associations of interstitial lung abnormalities with cancer diagnoses and mortality , 2020, European Respiratory Journal.

[10]  D. Lynch,et al.  Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. , 2020, The Lancet. Respiratory medicine.

[11]  N. Zhong,et al.  Serum SP-A and KL-6 levels can predict the improvement and deterioration of patients with interstitial pneumonia with autoimmune features , 2020, BMC Pulmonary Medicine.

[12]  K. Brown,et al.  Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype. , 2020, Chest.

[13]  Hafiz Muhammad Waseem,et al.  Plasma Surfactant Protein-A Levels In Healthy Subjects And Chronic Obstructive Pulmonary Disease Patients. , 2020, Journal of Ayub Medical College, Abbottabad : JAMC.

[14]  I. Noth,et al.  Circulating Plasma Biomarkers of Progressive Interstitial Lung Disease. , 2020, American journal of respiratory and critical care medicine.

[15]  B. Saez,et al.  Use of serum KL-6 level for detecting patients with restrictive allograft syndrome after lung transplantation , 2020, PloS one.

[16]  Hiromasa Yamamoto,et al.  Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. , 2019, Respiratory investigation.

[17]  D. Lynch,et al.  Interstitial Lung Abnormality: Recognition and Perspectives. , 2019, Radiology.

[18]  C. Carvalho,et al.  Imaging in idiopathic pulmonary fibrosis: diagnosis and mimics , 2019, Clinics.

[19]  Sang Min Lee,et al.  Analytical and Clinical Performance of the Nanopia Krebs von den Lungen 6 Assay in Korean Patients With Interstitial Lung Diseases , 2019, Annals of laboratory medicine.

[20]  J. Wesenberg,et al.  Comparison of 13 Commercially Available Cardiac Troponin Assays in a Multicenter North American Study. , 2017, The Journal of Applied Laboratory Medicine.

[21]  J. Guiot,et al.  Blood Biomarkers in Idiopathic Pulmonary Fibrosis , 2017, Lung.

[22]  F. Martinez,et al.  Plasma Surfactant Protein-D, Matrix Metalloproteinase-7, and Osteopontin Index Distinguishes Idiopathic Pulmonary Fibrosis from Other Idiopathic Interstitial Pneumonias. , 2016, American journal of respiratory and critical care medicine.

[23]  E. Aliouat,et al.  Surfactant proteins, SP-A and SP-D, in respiratory fungal infections: their role in the inflammatory response , 2016, Respiratory Research.

[24]  N. Kohno,et al.  Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis , 2016, Disease markers.

[25]  L. Richeldi,et al.  Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history , 2016, Respirology.

[26]  Luca Busetto,et al.  European Guidelines for Obesity Management in Adults , 2015, Obesity Facts.

[27]  Tom Long,et al.  Verifying performance characteristics of quantitative analytical systems: calibration verification, linearity, and analytical measurement range. , 2014, Archives of pathology & laboratory medicine.

[28]  Shandra L. Protzko,et al.  An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. , 2013, American journal of respiratory and critical care medicine.

[29]  G. Engström,et al.  Blood biomarkers and measures of pulmonary function--a study from the Swedish twin registry. , 2012, Respiratory medicine.

[30]  N. Kohno,et al.  Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. , 2012, Respiratory investigation.

[31]  M. Ebina,et al.  The Diagnostic Value of the Interstitial Biomarkers KL-6 and SP-D for the Degree of Fibrosis in Combined Pulmonary Fibrosis and Emphysema , 2012, Pulmonary medicine.

[32]  M. Hallworth,et al.  The ‘70% claim’: what is the evidence base? , 2011, Annals of clinical biochemistry.

[33]  F. Bonella,et al.  Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement. , 2011, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[34]  N. Kohno,et al.  Levels of Surfactant Proteins A and D and KL-6 Are Elevated in the Induced Sputum of Chronic Obstructive Pulmonary Disease Patients: A Sequential Sputum Analysis , 2011, Respiration.

[35]  D. Hansell,et al.  Lung morphology in the elderly: comparative CT study of subjects over 75 years old versus those under 55 years old. , 2009, Radiology.

[36]  V. Torri,et al.  Differential diagnosis and management of focal ground-glass opacities , 2009, European Respiratory Journal.

[37]  G. Vignati,et al.  Standardization of PSA Measures: A Reappraisal and an Experience with WHO Calibration of Beckman Coulter Access Hybritech Total and Free PSA , 2007 .

[38]  S. Abe,et al.  Monitoring markers of disease activity for interstitial lung diseases with serum surfactant proteins A and D , 2006, Respirology.

[39]  F. Martinez,et al.  Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. , 2003, American journal of respiratory and critical care medicine.

[40]  C. Hermans,et al.  Serum levels of CC16, SP-A and SP-B reflect tobacco-smoke exposure in asymptomatic subjects , 2002, European Respiratory Journal.

[41]  S. Abe,et al.  Diagnostic significance of surfactant proteins A and D in sera from patients with radiation pneumonitis. , 2001, The European respiratory journal.

[42]  S. Kitamura,et al.  KL-6: a serum marker for interstitial pneumonia. , 1995, Chest.

[43]  M. Yoshimi,et al.  Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis. , 2017, Respiratory investigation.

[44]  W. Catalona,et al.  20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials--analysis of 1098 patients in four centers. , 2009, The International journal of biological markers.

[45]  J. Itami,et al.  Serum levels of KL-6 for predicting the occurrence of radiation pneumonitis after stereotactic radiotherapy for lung tumors. , 2004, Chest.